A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

A pill from Eli Lilly helped patients improve their blood sugar and shed weight, results that could propel the ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were ...

Injectable medications originally developed for the treatment of diabetes are also effective for weight loss and have surged ...